• 1
    Carson C, Giuliano F, Goldstein I et al. The ‘effectiveness’ scale–therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 2004; 16: 20713
  • 2
    Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res 2004; 16: 308
  • 3
    O'Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol 2006; 175: 105862
  • 4
    Cappelleri JC, Althof SE, O'Leary MP, Tseng LJ, the US and International SEAR Study Groups. Analysis of single items on the Self-Esteem And Relationship questionnaire in men treated with sildenafil citrate for erectile dysfunction: results of two double blind, placebo-controlled trials. BJU Int 2008; 101: 8616
  • 5
    Althof SE, O'Leary MP, Cappelleri JC et al. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med 2006; 3: 5219
  • 6
    McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 1639
  • 7
    Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007; 8: 31
  • 8
    US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009; 74: 651323
  • 9
    Committee for Medicinal Products for Human Use (CHMP). Guideline on the Choice of the Noninferiority Margin. London: European Medicines Agency, 2005
  • 10
    Senn S. Disappointing dichotomies. Pharma Stat 2003; 2: 23940
  • 11
    Altman DG. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC, 1991
  • 12
    SAS Institute Inc. SAS/STAT® User's Guide. Version 9.2. Cary, NC: SAS Institute Inc., 2008
  • 13
    Cappelleri JC, Althof SE, O'Leary MP et al. Clinically meaningful improvement on the Self-Esteem And Relationship questionnaire in men with erectile dysfunction. Qual Life Res 2007; 16: 120310
  • 14
    Fehnel SE, McLeod LD, Brandman J et al. Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res 2002; 11: 80916
  • 15
    Bushmakin AG, Cappelleri JC. A note on cumulative distribution functions for patient-reported outcomes. PRO Newsletter 2011; 45: 112
  • 16
    Dubois D, Gilet H, Viala-Danten M, Tack J. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 2010; 22: e5463
  • 17
    Atkinson AJ Jr, Abernethy DR, Daniels CE, Dedrick RL, Markey SP. Principles of Clinical Pharmacology. Second Edition. London: Elsevier Inc., 2007
  • 18
    O'Leary MP, Rhodes T, Girman CJ et al. Distribution of the Brief Male Sexual Inventory in community men. Int J Impot Res 2003; 15: 18591
  • 19
    Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 56374
  • 20
    Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005; 14: 84955
  • 21
    Coyne K, Matza L, Thomspon C, Kopp Z, Khullar V. Determining the importance of change in the Overactive Bladder Questionnaire. J Urol 2006; 176: 62732
  • 22
    Wei J, Dunn R, Litwin M, Sandler H, Sanda M. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899905
  • 23
    Chang P, Szymanski KM, Dunn RL et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186: 86572